Sorafenib in Elderly Patients with Advanced Hepatocellular Carcinoma: A Case Series

Publisher： Karger

E-ISSN： 1423-0232|84|5|265-272

ISSN： 0030-2414

Source： Oncology, Vol.84, Iss.5, 2013-02, pp. : 265-272

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Sunitinib in Patients with Advanced Hepatocellular Carcinoma after Progression under Sorafenib Treatment

By  

Oncology, Vol. 79, Iss. 1-2, 2010-11 ,pp. : 85-92

Karger

Access to resources Recommend Favorite

Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib

By  

HEPATOLOGY, Vol. 62, Iss. 3, 2015-09 ,pp. : 784-791

John Wiley & Sons Inc

Access to resources Recommend Favorite

Safety and Efficacy of Sorafenib in Elderly Patients Treated in the North American Advanced Renal Cell Carcinoma Sorafenib Expanded Access Program

By  

Oncology, Vol. 78, Iss. 5-6, 2010-08 ,pp. : 340-347

Karger

Access to resources Recommend Favorite

Sorafenib Dose Escalation in the Treatment of Advanced Hepatocellular Carcinoma

By  

Oncology, Vol. 82, Iss. 2, 2012-02 ,pp. : 119-125

Karger

Access to resources Recommend Favorite

Early Decrease in α-Fetoprotein, but Not Des-γ-Carboxy Prothrombin, Predicts Sorafenib Efficacy in Patients with Advanced Hepatocellular Carcinoma

By  

Oncology, Vol. 81, Iss. 3-4, 2011-11 ,pp. : 251-258

Karger

Access to resources Recommend Favorite